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Long-Term Incidence and Timing of
Intraocular Hypertension after Intravitreal
Triamcinolone Acetonide Injection
Daniel B. Roth, MD,1 Varun Verma, MD,1 Tony Realini, MD,2 Jonathan L. Prenner, MD,1
William J. Feuer, MS,3 Robert D. Fechtner, MD4
Purpose: To describe the long-term incidence and timing of steroid-induced ocular hypertension after
intravitreal triamcinolone acetonide (IVTA) therapy.
Design: Retrospective case series of 929 eyes of 841 patients.
Participants: Patients with a variety of posterior segment disorders in a single group practice.
Intervention: Pars plana injection of IVTA.
Main Outcome Measures: Intraocular pressure (IOP) and requirement for glaucoma surgery.
Results: Overall, 929 eyes received ⱖ1 injections (mean, 1.6) of 4 mg of IVTA. During a mean follow-up
period of 14⫾6.9 months, the Kaplan–Meier cumulative incidences of IOP elevations ⬎21 mmHg at 6, 12, 18, and
24 months post-injection were 28.2%, 34.6%, 41.2%, and 44.6%, respectively; similarly, the incidences of eyes
with IOP measurements ⬎25 mmHg were 14.6%, 19.1%, 24.1%, and 28.2%, respectively. At the same time
points, IOP-lowering medications were required by 13.0%, 16.9%, 20.7%, and 24.2% of eyes, respectively. Only
3 eyes (0.3%) required IOP-lowering surgery. Preexisting glaucoma, younger age, and a history of an IOP
elevation after a previous IVTA injection were risk factors for IOP elevations after IVTA injection. The minimum and
maximum follow-up were 3 weeks and 37 months. The mean rate of attrition in this study was 3% per month.
Conclusions: Elevations in IOP after IVTA injection are common. Younger patients and eyes with preexisting
glaucoma or a history of a steroid response should be monitored more closely for IOP elevations after IVTA therapy.
Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed
in this paper. Ophthalmology 2009;116:455– 460 © 2009 by the American Academy of Ophthalmology.

Steroid-induced elevations of intraocular pressure (IOP)
were first reported ⬎40 years ago, when some eyes treated
with topical dexamethasone were noted to manifest significant IOP responses.1–3 Since then, steroid-induced ocular
hypertension has been observed after virtually every route
of administration for corticosteroids.4 The onset of this
phenomenon is variable after initiation of corticosteroid
therapy, and the magnitude of the steroid response is equally
variable, ranging from a rise of a few millimeters of mercury to dramatic rises of ⬎40 mmHg. Traditional IOPlowering therapy, including topical and oral medications,
laser trabeculoplasty,5–7 and incisional surgery, have all
shown efficacy in lowering steroid-induced elevations of
IOP. Definitive treatment consists of discontinuation of
steroid therapy, although this is not always practical or
possible given the nature and severity of the underlying
disease process requiring corticosteroid therapy. In addition,
the route of administration may also limit the ability to
discontinue therapy. In the setting of topical, oral, or parenteral administration, dosing can be discontinued upon the
onset of an IOP response. Depot injections, such as those
administered in the sub-Tenon’s space or the intravitreal
cavity, are more difficult to remove and thus pose a greater
clinical challenge.
Intravitreal injection of the corticosteroid triamcinolone
acetonide has been advocated for a number of posterior
© 2009 by the American Academy of Ophthalmology
Published by Elsevier Inc.

segment conditions, including age-related macular degeneration, ocular manifestations of diabetes including proliferative retinopathy and macular edema, retinal vein occlusions, and noninfectious posterior uveitis.8 Although the
safety and efficacy profile of intravitreal triamcinolone acetonide (IVTA) in these and other ocular conditions has not
been rigorously established through well-designed, randomized, clinical trials, it is clear that elevated IOP is a common
and serious side effect of IVTA therapy.4,8 The management
of IOP elevation after IVTA therapy is made difficult by the
inability to remove the inciting agent, the significant magnitude of IOP elevation in many cases, the long duration of
IOP elevation after even a single injection, and the failure of
conservative management to lower IOP to a safe range in a
significant minority of cases.
The purpose of this report is to describe the incidence
and characteristics of IOP elevations after intravitreal administration of triamcinolone acetonide, as observed in a series of
929 eyes of 841 patients from a single practice receiving ⱖ1
IVTA injections and followed for a mean of ⬎1 year.

Methods
This retrospective review followed 929 eyes of 841 consecutive
patients receiving ⱖ1 IVTA injection for a minimum of 3 months
post-injection. The study protocol was approved by the Robert
ISSN 0161-6420/09/$–see front matter
doi:10.1016/j.ophtha.2008.10.002
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Wood Johnson Medical School institutional review board. All
injections were given between June 2001 and June 2004. The
indications for IVTA therapy are given in Table 1. All intravitreal
injections of triamcinolone acetonide (4 mg) were given via sterile
technique, using a sterile lid speculum and after a drop of 5% to
10% iodine–povidine solution as described previously.9 All patients were examined 1 to 7 days after each injection, and then at
the discretion of the treating physician. Intraocular pressure was
assessed at every visit.
Data were collected by way of a retrospective review. The data
collected included diagnosis warranting IVTA therapy and dates of
injections and follow-up visits. At each visit, the following data
were recorded: visual acuity, IOP, and the occurrence of any
adverse events.
The incidence of IOP elevation, defined at thresholds of ⬎21
mmHg and ⬎25 mmHg, at 6, 12, 18, and 24 months after injection
was assessed using Kaplan–Meier analysis, as was the incidence of
medication use associated with IOP elevation at each of these time
points. The log-rank test was used to compare incidences in eyes
with and without preexisting glaucoma. Analyses with P⬍0.05
were considered significant. Mean values are reported ⫾ standard
deviation (SD). Cox multivariate proportional hazards regression
was used to investigate the independent effects of preexisting
glaucoma, age, indication for IVTA, and pseudophakia on the
incidence of pressure elevation.

Table 2. Frequency of Multiple Injections
No. of Injections

N

Percent

1
2
3
4
5
6
7

583
224
71
39
10
0
2

62.8
24.1
7.6
4.2
1.1
0
0.2

were 28.2% (95% confidence interval [CI], 26%–31%), 34.6%
(95% CI, 32%–38%), 41.2% (95% CI, 38%– 46%), and 44.6%
(95% CI, 41%–50%), respectively (Fig 1A) among all eyes receiving from 1 to 7 IVTA injections. Similarly, the cumulative proportions of eyes with IOP measurements ⬎25 mmHg were 14.6%,

Results
Overall, 929 eyes of 841 patients are included in this report.
Patients were 55% female of mean age 71.5⫾11.8 years, and the
mean follow-up time was 14⫾6.9 months. The number of injections ranged from 1 to 7 per eye (Table 2), with a mean of 1.6
injections per eye. Of the entire group, 88 eyes of 76 patients had
preexisting glaucoma. The minimum and maximum follow-up
were 3 weeks and 37 months. The mean rate of attrition in this
study was 3% per month.

Incidence of Steroid-Induced Ocular Hypertension
At 6, 12, 18, and 24 months, the cumulative Kaplan–Meier proportions of eyes with IOP measurements exceeding 21 mmHg
Table 1. Indications for Intravitreal Triamcinolone
Acetonide Injection
Indication

Frequency

Percent

Branch retinal vein occlusion
Choroidal neovascular membrane
Coats’ disease
Central retinal vein occlusion
Diabetic macular edema
Eales disease
Hemiretinal vein occlusion
Hypotony
Juxtafoveal telangectasis
Macular pucker
Postoperative cystoid macular edema
Radiation retinopathy
Retinitis pigmentosa associated cystoid macular
edema
Uveitis
Vitreomacular traction syndrome
Total

81
200
1
57
415
1
16
2
3
19
107
2
2

8.8
21.5
0.1
6.1
44.6
0.1
1.7
0.2
0.3
2.0
11.5
0.2
0.2

21
2
929

2.3
0.2
100
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Figure 1. A, Kaplan-Meier cumulative proportion of cases with incident
intraocular pressure (IOP) ⬎21 mmHg by months since initial intravitreal
triamcinolone acetonide (IVTA) injection for all eyes (solid line) and the
subset requiring only a single IVTA (dashed line). B, Kaplan–Meier
cumulative proportion of cases with incident IOP ⬎21 mmHg by months
since initial IVTA injection for cases with (dashed line) and without
(solid line) prior history of glaucoma.
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32.8% (95% CI, 30%–36%), respectively, at 1 year, among eyes
that did experience such an elevation the average time to it was
similar in the 2 groups. There was no significant difference (P ⫽
0.35) between the average increase in IOP at the time of the first
elevation in the eyes with prior history of glaucoma (9.5⫾4.2), and
those without (8.8⫾4.1). Among eyes with a single IVTA injection, the median time to the first IOP elevation in those with prior
glaucoma was 5.0 weeks compared with 6.3 weeks for eyes
without prior glaucoma (P ⫽ 0.18). The results for IOP measurements ⬎25 mmHg were similar.
There was no persuasive evidence that cases with previous
glaucoma were followed more closely than other cases. In eyes
with a prior history of glaucoma the mean number of visits until
the first IOP elevation was noted was 2.3⫾3.0, which was more,
but not significantly so (P ⫽ 0.13), than in the eyes without a prior
history of glaucoma (1.7⫾1.5 visits).
After accounting for prior history of glaucoma, a 10-year
increase in age is associated with a 16% reduction in risk (95% CI,
9%–22%; Cox regression) of IOP measurement ⬎21 (P⬍0.001)
and a 17% reduction in risk (95% CI, 9%–25%; Cox regression) of
IOP measurement ⬎25 mmHg (P ⫽ 0.001). Accounting for age
did not reduce the significance of the effect of prior history of
glaucoma (P ⬍ 0.001 for both 21 and 25 mmHg). The effects of
2 other variables, indication for treatment and pseudophakia at the
time of treatment, on the incidence of 21- and 25-mmHg IOP
elevations were also examined. After accounting for the highly
significant effects of prior history of glaucoma and age, neither of
these variables was statistically significant (all P⬎0.10).

Incidence of Intraocular Pressure-Lowering
Medication Use

Figure 2. A, Kaplan–Meier cumulative proportion of cases with incident
intraocular pressure (IOP) ⬎25 mmHg by months since initial intravitreal
triamcinolone acetonide (IVTA) injection for all eyes (solid line) and the
subset requiring only a single IVTA (dashed line). B, Kaplan–Meier
cumulative proportion of cases with incident IOP ⬎25 mmHg by months
since initial IVTA injection for cases with (dashed line) and without
(solid line) prior history of glaucoma.

19.1% 24.1%, and 28.2%, at the same time points, respectively
(Fig 2A). The risk of IOP elevation was greatest between weeks 2
through 5 post-IVTA injection and decreased subsequently thereafter; however, the incidence of a first pressure elevation continued
to increase throughout follow-up. Nine new cases of pressure
elevation were noted at or after 1 year after a single injection. Eight
of these were isolated elevations requiring no treatment, and 1 case
was noted after the eye underwent a subsequent surgery.

Effect of Preexisting Glaucoma and Age
As shown in Figs 1B and 2B, eyes with preexisting glaucoma were
more likely to manifest steroid-induced ocular hypertension than
eyes without preexisting glaucoma (both P⬍0.001). Although the
cumulative percentage with a pressure measurement ⬎21 mmHg
was substantially higher among cases with prior glaucoma than
those without, for example, 52.3% (95% CI, 41%– 63%) versus

At 6, 12, 18, and 24 months, the cumulative Kaplan–Meier proportions of eyes requiring the initiation or addition of IOP-lowing
medical therapy for 13.0%, 16.9%, 20.7%, and 24.2%, respectively (Fig 3A). As shown in Figure 3B, the likelihood of
requiring IOP-lowering therapy post-injection was similar in
eyes with and without preexisting glaucoma; eyes with preexisting glaucoma, however, required medications sooner after
injection than did eyes without preexisting glaucoma (P ⫽
0.002). Three eyes required surgical intervention for management of IOP, including 2 eyes that underwent trabeculectomy
and 1 eye that underwent diode cyclophotocoagulation.

Management after Intraocular Pressure Elevation
The 130 eyes with a single IVTA injection, without prior glaucoma, and that had follow-up after a pressure measurement ⬎21
mmHg were at risk of subsequent IOP elevation. These eyes had
a median of 5 further visits over a median of 11 months follow-up.
Of these, 36 (28%) had no further IOP measurements ⬎21 mmHg,
82 (63%) had 1 to 3 further IOP measurements ⬎21 mmHg, 9
(7%) had 4 to 6 further IOP measurements ⬎21 mmHg, and 3
(2%) had ⬎6 further IOP measurements ⬎21 mmHg. However,
many of these were pressures of ⱕ25 mmHg. Eighty-five eyes
(65%) had no further IOP measurements ⬎25 mmHg, 43 (33%)
had 1 to 3 IOP measurements ⬎25 mmHg, and 2 (2%) had ⬎3 IOP
measurements ⬎25 mmHg. Sixty-nine (58%) of the first IOP
measurements tested after the initial elevation, a median of 1
month later, were ⱕ21 mmHg.
Kaplan–Meier analysis demonstrated among eyes with ⱖ1 IOP
elevation that, by 3 months, a cumulative proportion of 12.3% had
subsequent IVTA injections. This increased to 22.3% at 6 months
and 34.1% at 1 year. There was no significant difference between
the rates of post-IOP elevation IVTA injections between subjects
with and without prior glaucoma (P ⫽ 0 .66; log-rank test).
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0.6 – 8.6) times higher than in eyes with an elevation before the
fourth injection. Similarly, the risk of a ⬎25-mmHg pressure
elevation after second or third IVTA injections was 5.5 (95% CI,
2.9 –10.4) and 2.9 (95% CI, 0.9 –9.3) times higher, respectively, in
eyes with than without an IOP elevation on a prior injection; too
few IOP measurements ⬎25 mmHg occurred after fourth injections to permit analysis.

Discussion

Figure 3. A, Kaplan–Meier cumulative proportion of cases requiring additional pressure lowering medications by months since initial intravitreal
triamcinolone acetonide (IVTA) injection for all eyes. B, Kaplan–Meier
cumulative proportion of cases requiring additional pressure-lowering medications by months since initial IVTA injection for cases with (dashed line)
and without (solid line) prior history of glaucoma.

Risk with Multiple Injections
After the initial injection, 250 of 929 eyes (26.9%) experienced an
IOP measurement ⬎21 mmHg before the first re-injection or loss to
follow-up; approximately half of these (134 [14.4%]) experienced an
IOP measurement exceeding 25 mmHg (Table 3). The incidence of
IOP elevation rose slightly after the second and third injections but
decreased after a fourth injection; but these small differences in
incidence rates may be due to a diminishing sample size.
Using Cox survival regression while excluding cases with prior
glaucoma, the risk of a ⬎21-mmHg elevation in pressure after the
second IVTA injection is 3.4 (95% CI, 2.2–5.2) times higher in
eyes with an elevation before the second injection (i.e., after the
first injection). The risk of a ⬎21-mmHg pressure elevation after
the third IVTA injection is 3.9 (95% CI, 1.8 – 8.4) times higher in
eyes with an elevation before the third injection (i.e., after either
the first or second injections or both). The risk of a ⬎21-mmHg
pressure elevation after the fourth IVTA injection is 2.2 (95% CI,

458

This study demonstrates that IOP measurements of ⬎21
mmHg after IVTA therapy are common, and although
many eyes with IOP elevation required medical therapy
to manage IOP, surgical intervention for IOP control was
rarely necessary.
In our series, 45.6% of eyes experienced an IOP measurement of ⬎21 mmHg within 2 years after IVTA therapy;
only 28.9% experienced an IOP measurement of ⬎25
mmHg. These rates compare favorably with other reports.
In a series of 89 eyes receiving ⱖ1 injections of 4 mg IVTA,
Smithen et al10 reported a 40.4% incidence of IOP elevation
to ⱖ24 mmHg over a mean follow-up period of 9.3 months.
A meta-analysis of 305 eyes receiving a single 20-mg IVTA
injection conducted by Jonas et al11 reported that 41.2% of
eyes experienced an IOP elevation ⬎21 mmHg over a mean
follow-up period of 10.4 months.
Subjects in our study received up to 7 IVTA injections at
the discretion of the treating physician throughout their
course of therapy. These real-world data reflect the fact that
many patients require ⬎1 IVTA injection for long-term
disease management. Interestingly, the overall incidence of
IOP elevation did not increase significantly with multiple
injections. One explanation for this may be the reluctance to
re-inject an eye that previously manifested a significant IOP
elevation after a prior injection. It is the investigator’s
practice to repeat injections, if indicated, even in eyes that
have previously exhibited an IOP elevation, unless the prior
IOP elevation was extremely high or recalcitrant to treatment. Alternatively, the progressively higher rate of IOP
elevation with successive injections described in Table 3
may be a result of the diminishing sample size receiving
greater numbers of injections; this is supported by the
significant overlap in the 95% confidence intervals for IOP
elevation rates after successive injections. This observation
that IOP elevation rates are relatively independent of the
number of injections given is supported by the reports by
Smithen et al10 and Shukla et al.11 Jonas et al12 reported
eyes receiving a single injection, while 36% of eyes in the
series by Smithen et al10 received multiple injections (compared with 37% in our series). Yet the incidence of IOP
elevation was remarkably similar in these 3 series: 41.2% in
Jonas’ single-injection series11 versus 40.4% and 45.6% in
Smithen et al10 and our multi-injection series, respectively.
Our analysis indicates that eyes are at maximum risk of
an IOP elevation from weeks 2 through 5 after IVTA. To
further assess the timing of IOP elevation, we examined
eyes receiving only a single injection and found that, although the onset of pressure increases for most cases occurred within 6 weeks, new-onset IOP elevation was noted
many months after the IVTA injection. These were fre-
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Table 3. Incidence of Intraocular Pressure (IOP) Elevation ⬎ 21 mmHg and ⬎ 25 mmHg after Each Intravitreal Triamcinolone
(IVTA) Injection
IOP Spike > 21 mmHg

IOP Spike > 25 mmHg

No. of
Injections

Total (n)

Mean Follow-up
(SD), mos

n

%

95% CI

n

%

95% CI

1
2
3
4
5
6
7

929
346
122
51
12
2
2

10.3 (6.5)
7.5 (5.2)
6.2 (4.8)
3.9 (3.4)
5.9 (4.9)
3.7 (0.05)
1.4 (1.3)

250
120
52
16
3
0
1

26.9
34.7
42.6
31.4
25.0
0
50.0

24.1–29.9
29.7–40.0
33.7–51.9
19.1–45.9
5.5–57.2
0.0–84.2
1.3–98.7

134
63
23
4
1
0
0

14.4
18.2
18.9
7.8
8.3
0
0

12.2–16.9
14.3–22.7
12.3–26.9
2.2–18.9
0.2–38.5
0.0–84.2
0.0–84.2

CI ⫽ confidence interval; SD ⫽ standard deviation.

quently isolated and did not require treatment. Our series,
lacking a comparison control group, cannot establish the
etiology of these very late-onset pressure increases.
Eyes experiencing an IOP elevation after IVTA therapy
were significantly more likely to rise again on re-injection
than eyes that did not develop an IOP elevation with prior
injections. Eyes with IOP elevation after the first injection
were 3.4 times more likely to rise on a subsequent injection
than eyes that did not rise after the first injection. Similarly, an
IOP elevation after the first or second injection (or both)
increased the risk of IOP elevation after the third injection by
3.9-fold. When re-injecting an eye with a history of IOP
elevation after previous IVTA injections, clinicians are advised
to monitor carefully for subsequent IOP elevation.
Preexisting glaucoma also increased the risk of experiencing an IOP elevation after IVTA therapy, as did younger
age, a finding previously reported by Shukla et al.12 Eyes
with preexisting glaucoma experienced IOP elevation more
commonly and more quickly than nonglaucomatous eyes.
Given that these eyes are likely to be more susceptible to
IOP-related optic nerve damage, IVTA therapy should be used
with caution in glaucomatous eyes, and careful follow-up is
necessary to identify steroid-related IOP elevation early and
institute appropriate IOP-lowering interventions promptly.
Elevation of the IOP in our study was easily managed
with IOP-lowering medications. The incidences of IOP
medication use at various time points closely resembles the
incidence of IOP elevation ⬎25 mmHg at corresponding
time points. This is consistent with the common clinical
practice of observing modest IOP elevations without treatment, and treating IOP measurements of ⬎25 mmHg. Interestingly, only 3 eyes in our series required surgical intervention for IOP control (3/929; [0.3%]). This is
comparable to the report by Jonas et al,11 in which 3 of 305
(1%) of eyes required incisional surgery for IOP control.
In conclusion, IVTA is a common therapy for a variety
of posterior segment conditions. Steroid-induced ocular hypertension is a well-known complication of IVTA therapy.
This report describes the incidence and severity of IOP
elevation in a large cohort of eyes undergoing a variable
course of IVTA injections, ranging from 1 to 7 injections.
Elevated IOP is common after IVTA therapy, and eyes with
preexisting glaucoma, as well as those with a history of an
IOP elevation after a prior IVTA injection are at increased

risk of steroid-induced ocular hypertension and should be
followed more closely after any IVTA injection. Elevations
in IOP were generally mild to moderate in magnitude and
easily controlled with medical IOP-lowering therapy. When
managed appropriately, the risk of steroid-induced ocular
hypertension should not be an absolute barrier to offering
IVTA therapy in appropriate patients.
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